{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T10:27:20Z","timestamp":1786616840117,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>The aim of this study was to investigate the effects of anticoagulation with DOACs and warfarin on the characteristics of chronic subdural hematomas (CSDHs), specifically, the size of the hematomas, the presence of midline shift and the effect on consciousness levels, measured via the Glasgow Coma Scale (GCS).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A multi-centre retrospective case series analysis from January 2015 to May 2020 was conducted. Patients who were anticoagulated with DOACs and warfarin were of primary interest. The CSDH characteristics that were focussed on included the size of the CSDH, midline shift and GCS. Chi-squared analysis and independent t-tests were conducted for inter-variable analysis. Relative risk was also calculated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Two thousand, six hundred seventy-five patients across two tertiary neurosurgical units referred with CSDHs were included in the analysis. 1799 patients were male (67.3%), with a mean age of 78.5\u00a0years. 905 patients (33.8%) were on antithrombotic therapy, with 298 patients (11.1%) on warfarin and 203 patients (7.6%) on DOACs. There were statistically significant associations between the type of antithrombotic medication and both midline shift and size of the CSDH (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), but not GCS (<jats:italic>p<\/jats:italic>\u2009=\u20090.1956). No significant difference in relative risk (RR) for impaired GCS was found between DOACs and warfarin (1.158 vs 1.174 respectively). Relative risk analysis revealed a safer profile for DOACs, with a lower risk of developing a larger sized hematoma (RR 0.887 v 1.021) and a reduced likelihood of midline shift (RR 0.858 VS 0.938), which was supported by effect size analysis using odd\u2019s ratios. Comparative risk analysis between DOACs and warfarin further demonstrated a higher risk of midline shift for patients on warfarin (RR 1.431), that trended towards statistical significance (<jats:italic>p<\/jats:italic>\u2009=\u20090.0511, 95% confidence interval 0.998\u20132.05).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>For CSDH patients, DOACs may potentially be a safer method of anticoagulation as opposed to warfarin as they appear to be linked to the development of smaller sized hematomas and reduced midline shift, although there was no significant difference in GCS between the groups. These features are known to reduce the risk of needing neurosurgical intervention for CSDH. This is important in influencing the management of an increasingly ageing, multi-morbid population on increasing amounts of anticoagulation medication.\n<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12883-025-04134-3","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T14:33:16Z","timestamp":1745677996000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Characteristics of chronic subdural haematomas related to DOACs vs warfarin"],"prefix":"10.1186","volume":"25","author":[{"given":"Gokul Raj","family":"Krishna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Sobieraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayan","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Pandit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Sheridan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richa","family":"Job","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alishba","family":"Rizvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lameesa","family":"Kaysor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaliya","family":"Ashik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"MacArthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Snowdon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ved","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Callum","family":"Tetlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Joshi","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,26]]},"reference":[{"issue":"4","key":"4134_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s10143-004-0337-6","volume":"27","author":"H Baechli","year":"2004","unstructured":"Baechli H, Nordmann A, Bucher HC, Gratzl O. Demographics and prevalent risk factors of chronic subdural haematoma: results of a large single-center cohort study. Neurosurg Rev. 2004;27(4):263\u20136.","journal-title":"Neurosurg Rev"},{"issue":"9","key":"4134_CR2","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1007\/s00701-021-04879-z","volume":"163","author":"DJ Stubbs","year":"2021","unstructured":"Stubbs DJ, Vivian ME, Davies BM, Ercole A, Burnstein R, Joannides AJ. Incidence of chronic subdural haematoma: a single-centre exploration of the effects of an ageing population with a review of the literature. Acta Neurochir (Wien). 2021;163(9):2629\u201337.","journal-title":"Acta Neurochir (Wien)"},{"issue":"8","key":"4134_CR3","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1001\/jama.2017.0639","volume":"317","author":"D Gaist","year":"2017","unstructured":"Gaist D, Garcia Rodriguez LA, Hellfritzsch M, Poulsen FR, Halle B, Hallas J, et al. Association of antithrombotic drug use with Subdural Hematoma risk. JAMA. 2017;317(8):836\u201346.","journal-title":"JAMA"},{"issue":"10","key":"4134_CR4","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/nrneurol.2014.163","volume":"10","author":"AG Kolias","year":"2014","unstructured":"Kolias AG, Chari A, Santarius T, Hutchinson PJ. Chronic subdural haematoma: modern management and emerging therapies. Nat Rev Neurol. 2014;10(10):570\u20138.","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"4134_CR5","doi-asserted-by":"publisher","first-page":"e68732","DOI":"10.1371\/journal.pone.0068732","volume":"8","author":"P De Bonis","year":"2013","unstructured":"De Bonis P, Trevisi G, de Waure C, Sferrazza A, Volpe M, Pompucci A, et al. Antiplatelet\/anticoagulant agents and chronic subdural hematoma in the elderly. PLoS One. 2013;8(7):e68732.","journal-title":"PLoS One"},{"key":"4134_CR6","doi-asserted-by":"crossref","unstructured":"Chen A, Stecker E, BAW. Direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc. 2020;9(13):e017559.","DOI":"10.1161\/JAHA.120.017559"},{"issue":"4","key":"4134_CR7","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","volume":"145","author":"AP Carnicelli","year":"2022","unstructured":"Carnicelli AP, Hong H, Connolly SJ, Eikelboom J, Giugliano RP, Morrow DA, et al. Direct Oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex. Circulation. 2022;145(4):242\u201355.","journal-title":"Circulation"},{"key":"4134_CR8","doi-asserted-by":"publisher","first-page":"e724","DOI":"10.1016\/j.wneu.2022.11.097","volume":"170","author":"S Biswas","year":"2023","unstructured":"Biswas S, MacArthur J, Sarkar V, Thompson H, Saleemi M, George KJ. Development and Validation of the Chronic Subdural HematOma Referral oUtcome Prediction Using Statistics (CHORUS) score: a retrospective study at a national tertiary center. World Neurosurg. 2023;170:e724\u201336.","journal-title":"World Neurosurg"},{"key":"4134_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.25259\/SNI_1086_2022","volume":"14","author":"S Biswas","year":"2023","unstructured":"Biswas S, MacArthur JI, Pandit A, McMenemy L, Sarkar V, Thompson H, et al. Predicting neurosurgical referral outcomes in patients with chronic subdural hematomas using machine learning algorithms - A multi-center feasibility study. Surg Neurol Int. 2023;14:22.","journal-title":"Surg Neurol Int"},{"issue":"3","key":"4134_CR10","first-page":"99","volume":"54","author":"A Kanat","year":"2010","unstructured":"Kanat A, Kayaci S, Yazar U, Kazdal H, Terzi Y. Chronic subdural hematoma in adults: why does it occur more often in males than females? Influence of patient\u2019s sexual gender on occurrence. J Neurosurg Sci. 2010;54(3):99\u2013103.","journal-title":"J Neurosurg Sci"},{"key":"4134_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clineuro.2015.01.009","volume":"131","author":"LA Marshman","year":"2015","unstructured":"Marshman LA, Manickam A, Carter D. Risk factors for chronic subdural haematoma formation do not account for the established male bias. Clin Neurol Neurosurg. 2015;131:1\u20134.","journal-title":"Clin Neurol Neurosurg"},{"issue":"3","key":"4134_CR12","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3340\/jkns.2012.52.3.234","volume":"52","author":"YW Sim","year":"2012","unstructured":"Sim YW, Min KS, Lee MS, Kim YG, Kim DH. Recent changes in risk factors of chronic subdural hematoma. J Korean Neurosurg Soc. 2012;52(3):234\u20139.","journal-title":"J Korean Neurosurg Soc"},{"issue":"13\u201314","key":"4134_CR13","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.3109\/02699052.2012.698364","volume":"26","author":"AI Yang","year":"2012","unstructured":"Yang AI, Balser DS, Mikheev A, Offen S, Huang JH, Babb J, et al. Cerebral atrophy is associated with development of chronic subdural haematoma. Brain Inj. 2012;26(13\u201314):1731\u20136.","journal-title":"Brain Inj"},{"issue":"1","key":"4134_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0022-510X(97)00141-X","volume":"152","author":"H Akiyama","year":"1997","unstructured":"Akiyama H, Meyer JS, Mortel KF, Terayama Y, Thornby JI, Konno S. Normal human aging: factors contributing to cerebral atrophy. J Neurol Sci. 1997;152(1):39\u201349.","journal-title":"J Neurol Sci"},{"key":"4134_CR15","doi-asserted-by":"publisher","first-page":"100300","DOI":"10.1016\/j.bas.2021.100300","volume":"1","author":"A Nouri","year":"2021","unstructured":"Nouri A, Gondar R, Schaller K, Meling T. Chronic Subdural Hematoma (cSDH): a review of the current state of the art. Brain Spine. 2021;1:100300.","journal-title":"Brain Spine"},{"issue":"10","key":"4134_CR16","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.jocn.2009.01.001","volume":"16","author":"P Lindvall","year":"2009","unstructured":"Lindvall P, Koskinen LO. Anticoagulants and antiplatelet agents and the risk of development and recurrence of chronic subdural haematomas. J Clin Neurosci. 2009;16(10):1287\u201390.","journal-title":"J Clin Neurosci"},{"key":"4134_CR17","unstructured":"Greater Manchester Combined Authority (GMCA). Census 2021 briefing. Manchester: Greater Manchester Combined Authority; 2023."},{"key":"4134_CR18","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1136\/bmj.p2567","volume":"383","author":"E Mahase","year":"2023","unstructured":"Mahase E. NHS England drive sees almost half a million people started on anticoagulant drugs. BMJ. 2023;383:2567.","journal-title":"BMJ"},{"issue":"4","key":"4134_CR19","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.3171\/2018.12.JNS183035","volume":"132","author":"M Rauhala","year":"2019","unstructured":"Rauhala M, Luoto TM, Huhtala H, Iverson GL, Niskakangas T, Ohman J, et al. The incidence of chronic subdural hematomas from 1990 to 2015 in a defined Finnish population. J Neurosurg. 2019;132(4):1147\u201357.","journal-title":"J Neurosurg"},{"issue":"4","key":"4134_CR20","doi-asserted-by":"publisher","first-page":"732","DOI":"10.3171\/2016.8.JNS16134","volume":"127","author":"PM Brennan","year":"2017","unstructured":"Brennan PM, Kolias AG, Joannides AJ, Shapey J, Marcus HJ, Gregson BA, et al. The management and outcome for patients with chronic subdural hematoma: a prospective, multicenter, observational cohort study in the United Kingdom. J Neurosurg. 2017;127(4):732\u20139.","journal-title":"J Neurosurg"},{"issue":"6","key":"4134_CR21","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1161\/STROKEAHA.114.005430","volume":"45","author":"BJ Connolly","year":"2014","unstructured":"Connolly BJ, Pearce LA, Hart RG. Vitamin K antagonists and risk of subdural hematoma: meta-analysis of randomized clinical trials. Stroke. 2014;45(6):1672\u20138.","journal-title":"Stroke"},{"issue":"8","key":"4134_CR22","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jocn.2004.12.013","volume":"13","author":"T Rust","year":"2006","unstructured":"Rust T, Kiemer N, Erasmus A. Chronic subdural haematomas and anticoagulation or anti-thrombotic therapy. J Clin Neurosci. 2006;13(8):823\u20137.","journal-title":"J Clin Neurosci"},{"issue":"14","key":"4134_CR23","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1212\/01.wnl.0000326895.58992.27","volume":"71","author":"ML Flaherty","year":"2008","unstructured":"Flaherty ML, Tao H, Haverbusch M, Sekar P, Kleindorfer D, Kissela B, et al. Warfarin use leads to larger intracerebral hematomas. Neurology. 2008;71(14):1084\u20139.","journal-title":"Neurology"},{"issue":"12","key":"4134_CR24","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1007\/s00415-019-09536-1","volume":"266","author":"DJ Seiffge","year":"2019","unstructured":"Seiffge DJ, Goeldlin MB, Tatlisumak T, Lyrer P, Fischer U, Engelter ST, et al. Meta-analysis of haematoma volume, haematoma expansion and mortality in intracerebral haemorrhage associated with oral anticoagulant use. J Neurol. 2019;266(12):3126\u201335.","journal-title":"J Neurol"},{"issue":"11","key":"4134_CR25","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1161\/01.STR.31.11.2558","volume":"31","author":"J Berwaerts","year":"2000","unstructured":"Berwaerts J, Dijkhuizen RS, Robb OJ, Webster J. Prediction of functional outcome and in-hospital mortality after admission with oral anticoagulant-related intracerebral hemorrhage. Stroke. 2000;31(11):2558\u201362.","journal-title":"Stroke"},{"issue":"7","key":"4134_CR26","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1161\/01.STR.24.7.987","volume":"24","author":"JP Broderick","year":"1993","unstructured":"Broderick JP, Brott TG, Duldner JE, Tomsick T, Huster G. Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality. Stroke. 1993;24(7):987\u201393.","journal-title":"Stroke."},{"issue":"13","key":"4134_CR27","doi-asserted-by":"publisher","first-page":"e1143","DOI":"10.1212\/WNL.0000000000005207","volume":"90","author":"R Kurogi","year":"2018","unstructured":"Kurogi R, Nishimura K, Nakai M, Kada A, Kamitani S, Nakagawara J, et al. Comparing intracerebral hemorrhages associated with direct oral anticoagulants or warfarin. Neurology. 2018;90(13):e1143\u20139.","journal-title":"Neurology"},{"issue":"8","key":"4134_CR28","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1212\/01.wnl.0000208408.98482.99","volume":"66","author":"SM Davis","year":"2006","unstructured":"Davis SM, Broderick J, Hennerici M, Brun NC, Diringer MN, Mayer SA, et al. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology. 2006;66(8):1175\u201381.","journal-title":"Neurology"},{"issue":"6","key":"4134_CR29","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1212\/01.WNL.0000138428.40673.83","volume":"63","author":"JJ Flibotte","year":"2004","unstructured":"Flibotte JJ, Hagan N, O\u2019Donnell J, Greenberg SM, Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology. 2004;63(6):1059\u201364.","journal-title":"Neurology"},{"issue":"1\u20132","key":"4134_CR30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jns.2013.06.020","volume":"332","author":"M Ma","year":"2013","unstructured":"Ma M, Meretoja A, Churilov L, Sharma GJ, Christensen S, Liu X, et al. Warfarin-associated intracerebral hemorrhage: volume, anticoagulation intensity and location. J Neurol Sci. 2013;332(1\u20132):75\u20139.","journal-title":"J Neurol Sci"},{"issue":"8","key":"4134_CR31","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1001\/archinte.164.8.880","volume":"164","author":"J Rosand","year":"2004","unstructured":"Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med. 2004;164(8):880\u20134.","journal-title":"Arch Intern Med"},{"key":"4134_CR32","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1016\/j.wneu.2018.06.124","volume":"118","author":"R Motoie","year":"2018","unstructured":"Motoie R, Karashima S, Otsuji R, Ren N, Nagaoka S, Maeda K, et al. Recurrence in 787 Patients with Chronic Subdural Hematoma: Retrospective Cohort Investigation of Associated Factors Including Direct Oral Anticoagulant Use. World Neurosurgery. 2018;118:e87\u201391.","journal-title":"World Neurosurgery"},{"key":"4134_CR33","doi-asserted-by":"publisher","first-page":"e855","DOI":"10.1016\/j.wneu.2018.08.177","volume":"120","author":"SM Ryu","year":"2018","unstructured":"Ryu SM, Yeon JY, Kong D-S, Hong S-C. Risk of Recurrent Chronic Subdural Hematoma Associated with Early Warfarin Resumption: A Matched Cohort Study. World Neurosurgery. 2018;120:e855\u201362.","journal-title":"World Neurosurgery"},{"issue":"7","key":"4134_CR34","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1089\/neu.2011.2074","volume":"29","author":"JY Yeon","year":"2012","unstructured":"Yeon JY, Kong DS, Hong SC. Safety of early warfarin resumption following burr hole drainage for warfarin-associated subacute or chronic subdural hemorrhage. J Neurotrauma. 2012;29(7):1334\u201341.","journal-title":"J Neurotrauma"},{"issue":"4","key":"4134_CR35","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1212\/WNL.0000000000002310","volume":"86","author":"D Wilson","year":"2016","unstructured":"Wilson D, Charidimou A, Shakeshaft C, Ambler G, White M, Cohen H, et al. Volume and functional outcome of intracerebral hemorrhage according to oral anticoagulant type. Neurology. 2016;86(4):360\u20136.","journal-title":"Neurology"},{"issue":"9","key":"4134_CR36","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1161\/STROKEAHA.114.006661","volume":"45","author":"J Hagii","year":"2014","unstructured":"Hagii J, Tomita H, Metoki N, Saito S, Shiroto H, Hitomi H, et al. Characteristics of intracerebral hemorrhage during rivaroxaban treatment: comparison with those during warfarin. Stroke. 2014;45(9):2805\u20137.","journal-title":"Stroke"},{"issue":"2","key":"4134_CR37","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/0049-3848(90)90148-6","volume":"59","author":"RA Fleck","year":"1990","unstructured":"Fleck RA, Rao LV, Rapaport SI, Varki N. Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody. Thromb Res. 1990;59(2):421\u201337.","journal-title":"Thromb Res"},{"issue":"1 Suppl","key":"4134_CR38","doi-asserted-by":"publisher","first-page":"8S","DOI":"10.1378\/chest.119.1_suppl.8S","volume":"119","author":"J Hirsh","year":"2001","unstructured":"Hirsh J, Dalen J, Anderson DR, Poller L, Bussey H, Ansell J, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001;119(1 Suppl):8S-21S.","journal-title":"Chest"},{"key":"4134_CR39","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40560-016-0144-5","volume":"4","author":"M Ieko","year":"2016","unstructured":"Ieko M, Naitoh S, Yoshida M, Takahashi N. Profiles of direct oral anticoagulants and clinical usage-dosage and dose regimen differences. J Intensive Care. 2016;4:19.","journal-title":"J Intensive Care"},{"key":"4134_CR40","doi-asserted-by":"crossref","unstructured":"Kustos SA, Fasinu PS. Direct-acting oral anticoagulants and their reversal agents-an update. Medicines (Basel). 2019;6(4):103\u201329.","DOI":"10.3390\/medicines6040103"},{"issue":"17","key":"4134_CR41","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1089\/neu.2020.7527","volume":"38","author":"L Wilson","year":"2021","unstructured":"Wilson L, Boase K, Nelson LD, et al. A manual for the glasgow outcome scale-extended interview. J Neurotrauma. 2021;38(17):2435\u201346. https:\/\/doi.org\/10.1089\/neu.2020.7527.","journal-title":"J Neurotrauma"},{"issue":"3","key":"4134_CR42","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1161\/01.STR.0000258355.23810.c6","volume":"38","author":"JL Banks","year":"2007","unstructured":"Banks JL, Marotta CA. Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials: a literature review and synthesis. Stroke. 2007;38(3):1091\u20136. https:\/\/doi.org\/10.1161\/01.STR.0000258355.23810.c6.","journal-title":"Stroke"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04134-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-025-04134-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04134-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T14:33:18Z","timestamp":1745677998000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-025-04134-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,26]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4134"],"URL":"https:\/\/doi.org\/10.1186\/s12883-025-04134-3","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,26]]},"assertion":[{"value":"3 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Consent to participate was waived by the Northwest Research and Innovation Institutional Review board, reference number: 22HIP11. All subsequent methods were performed in accordance with the relevant local guidelines and regulations. The study further adhered to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"184"}}